WO1998029151A1 - Solution, procede et dispositif de dialyse - Google Patents

Solution, procede et dispositif de dialyse Download PDF

Info

Publication number
WO1998029151A1
WO1998029151A1 PCT/EP1997/007319 EP9707319W WO9829151A1 WO 1998029151 A1 WO1998029151 A1 WO 1998029151A1 EP 9707319 W EP9707319 W EP 9707319W WO 9829151 A1 WO9829151 A1 WO 9829151A1
Authority
WO
WIPO (PCT)
Prior art keywords
dialysis
blood
dialysis solution
solution
citrate
Prior art date
Application number
PCT/EP1997/007319
Other languages
German (de)
English (en)
Inventor
Klaus Sodemann
Original Assignee
Klaus Sodemann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klaus Sodemann filed Critical Klaus Sodemann
Priority to EP97954979A priority Critical patent/EP1011748A1/fr
Publication of WO1998029151A1 publication Critical patent/WO1998029151A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3672—Means preventing coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/342—Adding solutions to the blood, e.g. substitution solutions
    • A61M1/3424—Substitution fluid path
    • A61M1/3431—Substitution fluid path upstream of the filter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/342—Adding solutions to the blood, e.g. substitution solutions
    • A61M1/3455—Substitution fluids
    • A61M1/3458—Substitution fluids having electrolytes not present in the dialysate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/342—Adding solutions to the blood, e.g. substitution solutions
    • A61M1/3455—Substitution fluids
    • A61M1/3465—Substitution fluids using dialysate as substitution fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3672—Means preventing coagulation
    • A61M1/3675—Deactivation

Definitions

  • the invention relates to a new dialysis solution for use in hemodia-filtration treatment and relates in particular to a calcium-free, citrate-containing dialysis solution which, after sterile filtration, is also used as a substitution solution, concentrates for its production and a device for its use.
  • the invention further relates to a new method using the dialysis solution.
  • anticoagulant substances used to date such as unfractionated heparin, low molecular weight heparin or also recently synthetically produced hirudin, basically have an influence on the coagulation situation of the human organism when used. Despite numerous efforts, the risk of bleeding from all of these methods has not yet been satisfactorily resolved.
  • DE-OS 41 14 908.4 describes a dialysis solution, the main advantage of which is that citrate ions are supplied to the blood from a citrate-containing dialysis solution by means of diffusion over the membrane of the filter.
  • a disadvantage of this method is that the anticoagulation does not start until the dialysis filter itself and the tube section between the blood removal needle (so-called "arterial needle") and the entry into the filter has no anticoagulation.
  • This procedure also has the disadvantage that undesirably high citrate concentrations are sometimes required for effective anticoagulation in the extracorporeal system.
  • the present invention is therefore based on the object of eliminating the disadvantages of the previous methods described above.
  • the invention relates to a dialysis solution for use in dialysis treatment with artificial kidneys, which is essentially free of calcium and magnesium and contains citrate and sodium ions, the amount of hydrogen carbonate in the solution not exceeding 32 mmol / l.
  • a method for extracorporeal treatment of a blood sample in which the dialysis solution according to the invention is added to the blood sample before the dialysis filter is reached in physiologically tolerable amounts.
  • the present invention relates to a device for carrying out the method in which the supply lines for blood and dialysis solution to the dialysis cell are connected in such a way that the dialysis solution is supplied to the blood before it reaches the dialysis cell.
  • the attached figure shows a schematic representation of the method of operation of the method according to the invention.
  • Blood is fed to the dialysis filter (2) via line (1) and, after treatment in the filter (4), returns to the starting point via line (3).
  • the current flow of the blood is regulated by a pump device (5).
  • the dialysis solution (13) according to the invention reaches the dialysis filter (2) via the supply line (6) and out of the filter again via the outgoing line (7).
  • Part of the dialysis solution is removed from the supply line (6) by means of line (8) and added to line (1) upstream of the filter unit (2).
  • the amount of dialysis solution removed can be regulated by a pump device (9).
  • Ca and Mg ions are added to the blood flowing back to the starting point via line (10), the flow rate of which can be regulated by a pump device (12).
  • the amount of citrate in the solution according to the invention is between about 1-15 mmol / 1, preferably between about 5 to 13 mmol / 1. Most preferably, the amount of citrate ions is 6 mmol / 1.
  • the amount of sodium ions is generally between 130 and 165 mmol / 1, with an amount of 133-145 mmol / 1 being preferred.
  • the most suitable amount of sodium ion has been found to be 138 mmol / l.
  • the amount of hydrogen carbonate contained in the dialysis solution according to the invention may not exceed 32 mmol according to the invention, since otherwise metabolic alkalosis can be expected.
  • the pH of the solution to be used is usually in the physiological range, a weakly acidic range in the range 4.8-7.5 having proven to be expedient. A range of 6.5-7.1 is preferred, and a pH of 6.8 is most preferred.
  • the pH of the solutions can be adjusted accordingly by the person skilled in the art on the basis of his general specialist knowledge and taking into account the respective patient data.
  • To adjust the pH it has proven to be appropriate to combine trisodium tricitrate and citric acid accordingly, so that, for example at a concentration of 5 mmol / 1 trisodium citrate, 1 mmol / 1 citric acid is added.
  • the osmolarity of the dilution used is not particularly limited, provided that it is physiologically acceptable.
  • the osmolarity is preferably in the range of approximately 260 mOsm / 1 - 330 mOsm / 1, and can be adjusted by the attending physician to the needs of the respective patient, if necessary.
  • the preferred osmolarity is between 280-300 mOsm / 1.
  • the osmolarity is preferably set by glucose, although other agents known in the art, such as amino acids, can also be used.
  • Glucose is particularly suitable because it is readily metabolically degradable and is also inexpensive. In addition, the effect on the respective patient can be determined simply by measuring blood sugar.
  • the dialysis solution according to the invention can also be in the form of a concentrate, for example to facilitate transportation, and can be diluted with an appropriate solution directly on the device if required.
  • the desired dilution, the pH value and the respective osmolarity of the feed solution can be set directly on the device by the dilution selected in each case.
  • citrate Smaller quantities of citrate can also be used. This is particularly advantageous for patients in whom citrate metabolism is disturbed due to liver disease, so that their metabolic capacity does not have to be exceeded by citrate by choosing extremely small amounts of citrate in the dialysis solution.
  • the small amounts of citrate also mean that the acid-base balance which is already disturbed in a dialysis patient is no longer adversely affected.
  • the combination of citrate with the specified small amounts of bicarbonate rather causes an advantageous buffering of the disturbed acid-base balance of the blood of a dialysis patient.
  • the solution according to the invention has also made it possible to completely dispense with the use of acetate in the dialysis solution, which had to be used in hydrogen carbonate dialysis in a concentration of 3 mmol / l.
  • the acetic acid can be replaced by citric acid, which is taken up into the patient's circulation without the problems associated with acetate, which have the disadvantageous effect on the circulation stability of the patient.
  • a portion of the citrate-containing, calcium- and magnesium-free solution with a reduced sodium hydrogen carbonate content is withdrawn from the dialysis circuit by a pump and, if necessary after sterile filtration, supplied to the blood before reaching the filter.
  • a preferred mixing ratio is achieved in that the blood flow is approximately five times higher than the flow of the citrate-containing solution supplied (at a blood flow of 250 ml / min, 50 ml / min of citrate-containing solution is therefore pumped into the blood).
  • a commercially available device from Fresenius Medical Care (MTS 4008 Mono) with some modifications can be used to carry out the method.
  • the pumps in the device are used by changing the control software so that the solutions according to the invention can be supplied by means of pumps.
  • the dialysis centers do not receive the dialysis solution, but rather concentrates that are diluted with reverse osmosis water for use on the patient in the dialysis machine.
  • 2 concentrates are used, one of which contains the cation sodium and the two anions hydrogen carbonate and trivalent citrate as soluble salts as the so-called basic concentrate.
  • the ion concentration ratio between citrate and sodium is as listed above.
  • the second concentrate (individual concentrate) optionally contains potassium chloride in a variable amount, as well as 1 mmol / 1 citric acid and optionally 2 g / 1 glucose monohydrate in order to increase the osmolarity.
  • the basic concentrate contains the essential components of the solution according to the invention and the individual concentrate enables adaptation to different operating conditions with increased / reduced potassium values of the respective patient.
  • An exemplary basic concentrate or individual concentrate contains the following components:
  • a concentration of 4 mmol / 1 citrate in the blood is generally sufficient to achieve an effective coagulation inhibition.
  • 6 mmol of the anion citrate are added to the final dialysis bath, 5 mmol / 1 deriving from trisodium citrate (basic concentrate) and 1 mmol / 1 from citric acid (individual concentrate).
  • Citric acid replaces the acetic acid typically added in bicarbonate dialysis.
  • the basic concentrate for citrate dialysis which contains sodium hydrogen carbonate and trisodium citrate, is diluted for use in the machine, preferably in a ratio of 1:15.
  • the second described individual concentrate containing glucose and citric acid is diluted in a ratio of 1: 150 for use . This dilution takes place in the machine, then the diluted concentrates are combined and represent the dialysis solution shown in claim 1.
  • the dialysis solution (13) prepared from basic and individual concentrate is pumped into the dialysis filter at a flow rate of 500 ml / min in counterflow to the blood.
  • typically 40 to 50 ml / min are branched off from the dialysis solution (13) by means of a further pump (9), which are fed to the so-called arterial blood tube after sterile filtration via a further filter (not shown).
  • the blood flow is typically 200 to 250 ml / min, so that a citrate concentration of 1.2 mmol / l in the blood flowing into the filter unit is achieved with the given setting in a ratio of approximately 5: 1.
  • the citrate content of the blood increases by diffusion from the citrate-containing dialysis solution to approximately 4 mmol / l, with which the blood ultimately leaves the filter. Due to this concentration and the lack of calcium and magnesium in the dialysis bath is in the filter and completely prevents blood clotting from the tube sections behind it.
  • a calcium / magnesium solution in the bypass is added via the lying venous needle. The flow rate for this solution is about 100 ml / hour and is caused by the pump (12). By adding calcium to the venous blood, coagulation is immediately normalized again.
  • a programmatic control can ensure that only all pumps can work at the same time, i.e. with the blood pump running, both ready-mixed dialysate must be provided and substitute solution must be pumped into the blood tube. It is also possible that calcium / magnesium chloride solution is simultaneously conveyed into the venous needle. If one pump stops, the other pumps must also be deactivated.
  • the ratio of blood flow to substitute solution flow is typically set to a predetermined value, preferably 5: 1, and the liquid balance is achieved automatically by the existing balance chamber system of the machine. With a typical treatment time of 4 to 5 hours, an additional 400 to 500 ml of ultrafiltration must be taken into account due to the calcium and magnesium chloride intake.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • External Artificial Organs (AREA)

Abstract

L'invention concerne une solution nouvelle de dialyse exempte de Ca et de Mg, qui contient du citrate comme anticoagulant et dont la teneur en hydrogénocarbonate de sodium ne dépasse pas 32 mmoles/l. Pendant la dialyse, une partie de la solution de dialyse est ajoutée au sang avant qu'il n'entre dans la cellule de dialyse. Un dispositif dans lequel la tubulure qui vient du patient et la tubulure d'alimentation de la cellule de dialyse en solution de dialyse sont réunies permet de mettre en oeuvre le procédé.
PCT/EP1997/007319 1996-12-30 1997-12-30 Solution, procede et dispositif de dialyse WO1998029151A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP97954979A EP1011748A1 (fr) 1996-12-30 1997-12-30 Solution, procede et dispositif de dialyse

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19654746.6 1996-12-30
DE19654746A DE19654746C2 (de) 1996-12-30 1996-12-30 Dialyselösung

Publications (1)

Publication Number Publication Date
WO1998029151A1 true WO1998029151A1 (fr) 1998-07-09

Family

ID=7816420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/007319 WO1998029151A1 (fr) 1996-12-30 1997-12-30 Solution, procede et dispositif de dialyse

Country Status (3)

Country Link
EP (1) EP1011748A1 (fr)
DE (1) DE19654746C2 (fr)
WO (1) WO1998029151A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002248165A (ja) * 2000-12-22 2002-09-03 Fresenius Medical Care Deutschland Gmbh 濃度測定方法及び透析装置
US6743191B1 (en) 1999-04-26 2004-06-01 Edwards Lifesciences Ag Substitution infusion fluid and citrate anticoagulation
GB2417420A (en) * 2004-08-19 2006-03-01 Aksys Ltd Citrate-based dialysate formulations
EP1721606A2 (fr) 1998-10-20 2006-11-15 Advanced Renal Technologies Compositions tamponnées pour dialyse
WO2006130065A1 (fr) 2005-05-30 2006-12-07 Gambro Lundia Ab Liquide de dialyse peritoneale
US7186420B2 (en) 1999-04-26 2007-03-06 Edwards Lifesciences Corporation Multi-part substitution infusion fluids and matching anticoagulants
JP2009516575A (ja) * 2005-11-22 2009-04-23 エドワーズ ライフサイエンシーズ コーポレイション 体外血液処理のためのクエン酸塩抗凝固システム
US7670491B2 (en) 1998-10-20 2010-03-02 Advanced Renal Technologies Buffered compositions for dialysis
US7862530B2 (en) 1999-09-22 2011-01-04 Advanced Renal Technologies High citrate dialysate and uses thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19748290B8 (de) 1997-10-31 2009-09-03 Fresenius Medical Care Deutschland Gmbh Lösung für die Peritonealdialyse
DE19912850B4 (de) 1999-03-22 2005-04-07 Fresenius Medical Care Deutschland Gmbh Lösung, insbesondere für Hämo- oder Peritonealdialyse, sowie Verfahren zu deren Herstellung
FR2800618B1 (fr) * 1999-11-08 2002-02-22 Bert Christophe Appareil d'hemofiltration permettant de controler, de facon independante, la concentration d'au moins deux substances ioniques dans le milieu interieur d'un patient
US6635026B1 (en) 1999-11-08 2003-10-21 Hospal Industrie Haemofiltration machine for independently controlling the concentration of a least two ionic substances in a patient's internal medium
IT1320024B1 (it) * 2000-04-07 2003-11-12 Gambro Dasco Spa Metodo per la regolazione della infusione in una macchina di dialisi e macchina di dialisi per l'applicazione del citato metodo.
US7935070B2 (en) 2005-01-28 2011-05-03 Fresenius Medical Care North America Systems and methods for dextrose containing peritoneal dialysis (PD) solutions with neutral pH and reduced glucose degradation product
CA2764838C (fr) 2009-06-17 2018-05-01 Fresenius Medical Care Holdings, Inc. Procedes de dialyse utilisant l'anticoagulation regionale au citrate
US9585810B2 (en) 2010-10-14 2017-03-07 Fresenius Medical Care Holdings, Inc. Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser
SI2826476T1 (sl) * 2013-07-16 2021-05-31 G.M.T. De Jong B.V. Dializna tekočina brez kalcija
EP3015124B1 (fr) * 2014-10-31 2017-08-16 B. Braun Avitum AG Système d'anticoagulation de citrate souple pendant un traitement sanguin extracorporel utilisant la précompensation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500309A (en) * 1982-05-07 1985-02-19 The Kansas University Endowment Association Method for regional anticoagulation during extracorporeal dialysis
WO1991006326A1 (fr) * 1989-10-31 1991-05-16 The Regents Of The University Of California Hemodialyse continue utilisant du citrate
DE4114908A1 (de) * 1991-05-07 1992-11-12 Klaus Dr Med Sodemann Dialyseloesung zur dialysebehandlung, konzentrat und vorrichtung zur dialysebehandlung
US5366630A (en) * 1991-08-14 1994-11-22 Hospal Industrie Artificial kidney and a method of controlling it

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4125819A1 (de) * 1991-08-03 1993-02-04 Rolf Prof Dr Med Zander Waessrige loesung und deren verwendung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500309A (en) * 1982-05-07 1985-02-19 The Kansas University Endowment Association Method for regional anticoagulation during extracorporeal dialysis
WO1991006326A1 (fr) * 1989-10-31 1991-05-16 The Regents Of The University Of California Hemodialyse continue utilisant du citrate
DE4114908A1 (de) * 1991-05-07 1992-11-12 Klaus Dr Med Sodemann Dialyseloesung zur dialysebehandlung, konzentrat und vorrichtung zur dialysebehandlung
US5366630A (en) * 1991-08-14 1994-11-22 Hospal Industrie Artificial kidney and a method of controlling it

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216247B2 (en) 1998-10-20 2015-12-22 Advanced Renal Technologies Buffered compositions for dialysis
EP1721606B1 (fr) * 1998-10-20 2013-09-11 Advanced Renal Technologies Compositions tamponnées pour dialyse
US7670491B2 (en) 1998-10-20 2010-03-02 Advanced Renal Technologies Buffered compositions for dialysis
EP1721606A2 (fr) 1998-10-20 2006-11-15 Advanced Renal Technologies Compositions tamponnées pour dialyse
EP2452685A1 (fr) * 1998-10-20 2012-05-16 Advanced Renal Technologies Compositions tamponnées pour dialyse
US7186420B2 (en) 1999-04-26 2007-03-06 Edwards Lifesciences Corporation Multi-part substitution infusion fluids and matching anticoagulants
US6743191B1 (en) 1999-04-26 2004-06-01 Edwards Lifesciences Ag Substitution infusion fluid and citrate anticoagulation
US7758900B2 (en) 1999-04-26 2010-07-20 Baxter International Inc. Multi-part substitution infusion fluids and matching anticoagulants
US8105258B2 (en) 1999-04-26 2012-01-31 Baxter International Inc. Citrate anticoagulation system for extracorporeal blood treatments
US8864699B2 (en) 1999-09-22 2014-10-21 Advanced Renal Technologies High citrate dialysate and uses thereof
US7862530B2 (en) 1999-09-22 2011-01-04 Advanced Renal Technologies High citrate dialysate and uses thereof
JP2002248165A (ja) * 2000-12-22 2002-09-03 Fresenius Medical Care Deutschland Gmbh 濃度測定方法及び透析装置
JP4558249B2 (ja) * 2000-12-22 2010-10-06 フレゼニウス メディカル ケアー ドイチュラント ゲゼルシャフト ミット ベシュレンクテル ハフツング 透析装置及びその作動方法
GB2417420A (en) * 2004-08-19 2006-03-01 Aksys Ltd Citrate-based dialysate formulations
WO2006130065A1 (fr) 2005-05-30 2006-12-07 Gambro Lundia Ab Liquide de dialyse peritoneale
US8367731B2 (en) 2005-05-30 2013-02-05 Fresenius Medical Care Deutschland Gmbh Peritoneal dialysis fluid
EP1890686A4 (fr) * 2005-05-30 2009-11-11 Gambro Lundia Ab Liquide de dialyse peritoneale
EP1890686A1 (fr) * 2005-05-30 2008-02-27 Gambro Lundia AB Liquide de dialyse peritoneale
JP2009516575A (ja) * 2005-11-22 2009-04-23 エドワーズ ライフサイエンシーズ コーポレイション 体外血液処理のためのクエン酸塩抗凝固システム

Also Published As

Publication number Publication date
DE19654746C2 (de) 2000-05-11
EP1011748A1 (fr) 2000-06-28
DE19654746A1 (de) 1998-07-02

Similar Documents

Publication Publication Date Title
DE19654746C2 (de) Dialyselösung
DE4230513C1 (de) Vorrichtung zur Entfernung von Aluminiumionen aus Blut und Lösung zur Verwendung in der Vorrichtung
DE69929555T2 (de) Verwendung einer Flüssigkeit zur Herstellung einer Dialyselösung für die kontinuierliche rezirkulierende Peritonealdialyse
DE69834589T2 (de) Verfahren zur Kontrolle der Natriumkonzentration eines Dialysats nach Verordnung
DE60027266T3 (de) Vorrichtung zur Aufbereitung einer medizinischen Flüssigkeit
DE69938035T2 (de) Sicherheitseinrichtung für dialysemaschine sowie verfahren zum aktivieren der sicherheitseinrichtung
DE10339342B3 (de) Blutbehandlungsvorrichtung
DE69834034T2 (de) Vorrichtung zum berechnen von der dialyseeffizienz
DE60031966T2 (de) Extrakorporaler kreislauf
EP1615680B1 (fr) Dispositif d'hemodialyse
EP2023972B1 (fr) Dispositif et procédé de commande d'un système de traitement sanguin extracorporel
DE60037408T2 (de) Vorrichtung zur Hämodialyse
EP0956872B1 (fr) Appareil de purification du sang
EP2249898B1 (fr) Procédé de détermination de la fraction de recirculation dans une fistule et/ou de la recirculation cardiopulmonaire, par rapport à la somme de la recirculation dans la fistule et de la recirculation cardiopulmonaire
DE60127657T2 (de) Blutreinigungssystem
DE60037233T2 (de) Hämofiltrationsvorrichtung
WO2009065611A1 (fr) Procédé et dispositif pour déterminer la recirculation dans une fistule ou la recirculation cardiopulmonaire, et dispositif de traitement du sang pourvu d'un dispositif pour déterminer la circulation en fistule ou la part de recirculation cardiopulmonaire
EP1576341A1 (fr) Procede et dispositif de determination du flux sanguin dans une conduite de circulation sanguine
DE19854338B4 (de) Verfahren und Einrichtung zur Nierenersatztherapie
DE102012011196A1 (de) Vorrichtung zur extrakorporalen Blutbehandlung und Verfahren zur Vorgabe eines initialen Behandlungsmodus für eine extrakorporale Blutbehandlungsvorrichtung
EP3177339B1 (fr) Procédé de lavage d'un circuit de sang extracorporel
DE4114908A1 (de) Dialyseloesung zur dialysebehandlung, konzentrat und vorrichtung zur dialysebehandlung
DE60315118T2 (de) Vorrichtung zur extrakorporalen Blutbehandlung durch Zitratantikoagulation
DE10245619B4 (de) Verfahren zur Blutrückgabe aus einer Blutbehandlungsvorrichtung und Vorrichtung zur Durchführung des Verfahrens
WO2016046177A1 (fr) Procédé et dispositifs pour la préparation d'une circulation sanguine extracorporelle pour le traitement du sang

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997954979

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997954979

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997954979

Country of ref document: EP